New STELARA data show inhibition of joint destruction in active psoriatic arthritis

(Tonic Life Communications USA) New findings from two integrated Phase 3 Janssen Research & Development, LLC-sponsored studies showed treatment with STELARA (ustekinumab) resulted in significantly greater inhibition of structural damage in patients with active psoriatic arthritis compared with placebo. These results are being presented during the 2013 Annual Meeting of the American College of Rheumatology.
Source: EurekAlert! - Medicine and Health - Category: Global & Universal Source Type: news